Literature DB >> 18953676

Psychosocial morbidity in acromegaly: a study from India.

Surendra Kumar Mattoo1, Anil Kumar Bhansali, Nitin Gupta, Sandeep Grover, Ramma Malhotra.   

Abstract

To study the psychosocial profile of patients of acromegaly in a developing country setting. Seventeen patients with acromegaly underwent a cross-sectional assessment regarding their socio-demographic and clinical profile, life events, social support, coping, dysfunction, quality of life and psychiatric morbidity. Seventeen demographically matched healthy participants (free from psychological morbidity) acted as the control group. The acromegaly group had predominance of urban married males (64.7%) with mean age 36.05 +/- 17.06 years (range = 15-61), and mean duration of illness of 36.05 +/- 42.5 (range = 4-240) months. Six subjects (i.e., GHQ-positive group) scored positive (indicating presence of psychiatric morbidity) on the General Health Questionnaire-12 giving a psychiatric morbidity rate of 33.33%, with five fulfilling an ICD-10 diagnosis. Compared to the GHQ-negative group, the GHQ-positive group had more number of life events in the entire lifetime, used significantly more number of emotional coping strategies, had more dysfunction, and poorer quality of life (in domains of physical health, social relationship, and general well-being). Psychiatric morbidity occurs in a significant percentage of patients with acromegaly. Presence of psychiatric morbidity is associated with dysfunction and poorer quality of life.

Entities:  

Mesh:

Year:  2008        PMID: 18953676     DOI: 10.1007/s12020-008-9112-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

Review 1.  Investigation protocol: acromegaly and its investigation.

Authors:  E Duncan; J A Wass
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

2.  The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group.

Authors:  S M Skevington; M Lotfy; K A O'Connell
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

Review 3.  An overview of the epidemiology and genetics of acromegaly.

Authors:  A F Daly; P Petrossians; A Beckers
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

4.  Psychiatric morbidity in vitiligo: prevalence and correlates in India.

Authors:  S K Mattoo; S Handa; I Kaur; N Gupta; R Malhotra
Journal:  J Eur Acad Dermatol Venereol       Date:  2002-11       Impact factor: 6.166

5.  [Paranoid-hallucinatory psychoses in acromegaly].

Authors:  D B Schulte
Journal:  Schweiz Arch Neurol Neurochir Psychiatr       Date:  1976

6.  A case of acromegaly and gigantism with depression.

Authors:  T L Avery
Journal:  Br J Psychiatry       Date:  1973-05       Impact factor: 9.319

7.  Acromegaly and depression.

Authors:  A Margo
Journal:  Br J Psychiatry       Date:  1981-11       Impact factor: 9.319

8.  A factor analytical study of the Comprehensive Psychopathological Rating Scale among patients with anxiety and depressive disorders.

Authors:  E W Martinsen; S Friis; A Hoffart
Journal:  Acta Psychiatr Scand       Date:  1989-11       Impact factor: 6.392

9.  Multiple hormone responses to clonidine administration in depressed patients and healthy volunteers.

Authors:  J D Amsterdam; G Maislin; B Skolnick; N Berwish; A Winokur
Journal:  Biol Psychiatry       Date:  1989-07       Impact factor: 13.382

10.  Validation of family interaction patterns scale.

Authors:  R S Bhatti; D K Subba Krishna; B L Ageira
Journal:  Indian J Psychiatry       Date:  1986-07       Impact factor: 1.759

View more
  7 in total

Review 1.  Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies.

Authors:  Cornelie D Andela; Margreet Scharloo; Alberto M Pereira; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

2.  Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Authors:  Panagiotis Anagnostis; Zoe A Efstathiadou; Maria Charizopoulou; Despina Selalmatzidou; Eleni Karathanasi; Maria Poulasouchidou; Marina Kita
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

Review 3.  Cognitive-behavioral therapy improves the quality of life of patients with acromegaly.

Authors:  Lia Silvia Kunzler; Luciana Ansaneli Naves; Luiz Augusto Casulari
Journal:  Pituitary       Date:  2018-06       Impact factor: 4.107

4.  State of Consultation-Liaison Psychiatry in India: Current status and vision for future.

Authors:  Sandeep Grover
Journal:  Indian J Psychiatry       Date:  2011-07       Impact factor: 1.759

5.  To study the impact of diabetic retinopathy on quality of life in Indian diabetic patients.

Authors:  Jyoti Deswal; Subina Narang; Nitin Gupta; Jitender Jinagal; Meenakshi Sindhu
Journal:  Indian J Ophthalmol       Date:  2020-05       Impact factor: 1.848

6.  Development and validation of the Social Capital Assessment Tool in pregnancy for Maternal Health in Low and middle income countries (LSCAT-MH).

Authors:  Thilini C Agampodi; Suneth B Agampodi; Nick Glozier; T A Lelwala; K D P S Sirisena; Sisira Siribaddana
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

7.  Pituitary Macroadenoma Presenting with Multiple Psychiatric Complications.

Authors:  Mamta Sood; Bichitra Nanda Patra; Alok Agrawal; Sudhir K Khandelwal
Journal:  Indian J Psychol Med       Date:  2015 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.